Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Inflammatory Bowel Disease III: Crohn's Disease

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An implementation science approach to geriatric screening in an emergency department.

Journal of the American Geriatrics Society·2021

Same author

Pharmacogenomics and drug development: the impact of US FDA postapproval tracking on clinical pharmacology.

Personalized medicine·2018

Same author

An integrative genomic analysis identifies Bhmt2 as a diet-dependent genetic factor protecting against acetaminophen-induced liver toxicity.

Genome research·2009

Same author

Tulane after katrina.

Ophthalmology·2008

Same author

In silico and in vitro pharmacogenetic analysis in mice.

Proceedings of the National Academy of Sciences of the United States of America·2007

Same author

In silico pharmacogenetics of warfarin metabolism.

Nature biotechnology·2006

Same journal

Comparative Distribution of High-Risk Human Papillomavirus (HPV) Genotypes in India vs World Health Organization Regions and Countries: Implications for HPV Vaccination.

Ochsner journal·2026

Same journal

Development and Implementation of a Radiation Safety Screening Protocol for a Clinical Study Using Amyloid Positron Emission Tomography Imaging.

Ochsner journal·2026

Same journal

A History of Vena Cava Interruption to Treat Pulmonary Embolism: The Ben Hogan Case.

Ochsner journal·2026

Same journal

Type 1 Collagen/Poly-L-Lactic Acid Biocomposite Augmentation of a Nontraumatic Symptomatic Complete Rotator Cuff Tear.

Ochsner journal·2026

Same journal

Spurious Plasma Adrenocorticotropic Hormone Level in a Patient With Adrenal Cushing Syndrome.

Ochsner journal·2026

Same journal

Revumenib-Induced QTc Prolongation Leading to Multiple Episodes of Torsades de Pointes and Ventricular Arrhythmias.

Ochsner journal·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Infliximab-associated Chiasmopathy.

Erin Farrell¹, Joel G Sacks

¹Department of Ophthalmology, Ochsner Clinic Foundation, New Orleans, LA.

Ochsner Journal

|May 24, 2011

Summary

This summary is machine-generated.

Tumor necrosis factor-alpha antagonists, like infliximab, may cause optic neuropathy. Discontinuing infliximab therapy in a rheumatoid arthritis patient led to significant vision improvement.

Keywords:

infliximab optic neuropathy

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Related Experiment Videos

Last Updated: Jun 1, 2026

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Area of Science:

Ophthalmology
Rheumatology
Immunology

Background:

Tumor necrosis factor-alpha (TNF-a) antagonists are used to treat inflammatory conditions like rheumatoid arthritis.
Optic neuropathy has been anecdotally linked to TNF-a antagonist use.

Purpose of the Study:

To report a case of optic neuropathy potentially associated with infliximab therapy.
To highlight the visual field defects and subsequent recovery.

Main Methods:

A case report detailing a patient's experience with decreased vision after initiating infliximab.
Visual field testing was performed to assess the extent of visual impairment.
Treatment involved discontinuation of infliximab.

Main Results:

The patient developed bitemporal hemianopic scotomas, indicative of optic chiasm involvement.
Following infliximab cessation, the patient showed marked improvement in visual acuity and visual fields.

Conclusions:

Infliximab therapy may be associated with optic neuropathy.
Discontinuation of the drug can lead to visual recovery in affected patients.